EndoPredict breast cancer testing

Results That Help You tailor breast cancer treatment decisions

EndoPredict provides three separate results you and your patient can use when determining the treatments that are right for them.

EndoPredict® helps make surgical and treatment decisions using a next generation prognostic test that predicts individual risk of early and late recurrence across years 0-15.

Confidently make chemotherapy decisions with your patient’s individualized absolute chemotherapy benefit.

Make informed extended endocrine therapy decisions with the only prognostic test that predicts distant recurrence up to 15 years at the time of diagnosis.

Accurate. Affordable. Accessible.

Guaranteeing results that are Accurate

Confident decision-making starts with identification of the true low-risk group of patients.

EndoPredict is a next-generation test validated in over 4,000 patients with ER+, HER2–, N0 and N1 disease and provides robust 10-year prognostic results and an individualized absolute chemotherapy benefit, specifically demonstrating superior prognostic performance in node-positive disease over the leading competitor.

EndoPredict receives treatment implications for chemo-prediction from NCCN (see Table BINV-N 3 of 4), ASCO, St. Gallen and ESMO guidelines.

Ensuring tests that are Affordable

Because patients and their families use test results to make life saving medical decisions, Myriad promises to provide affordable access to testing, a lifetime commitment to accurate results and comprehensive support for ALL appropriate patients and their families.

If a patient encounters ANY financial hardship associated with their bill, Myriad will work directly with the patient toward their complete satisfaction.

To learn more about The Myriad Promise, click below.

Making answers Accessible

  • The EndoPredict report provides your patient with a clear, individualized distant recurrence risk for years 0-10 based on her tumor’s specific biology and pathology.
  • Your patient will receive an individualized absolute chemotherapy benefit specific to her tumor.
Know at the time of diagnosis the distant risk of recurrence at 5-15 years and whether your patient might safely forego extended endocrine therapy.